Free Prostate Cancer Screening at Weill Cornell on September 19th

6th Annual Free Prostate Cancer Screening

When: Wednesday, September 19th
7:00 am to 5:00 pm
Where: New York-Presbyterian Hospital
525 East 68th Street (at York Avenue)
Payson Pavilion 2nd floor, Room F260
  • No appointment necessary for men over 40
  • Screening involves a PSA blood test and a prostate (DRE) exam
  • This is a screening test and is not for men already diagnosed with prostate cancer

For more information, please call (212) 746-5450


NYP/Weill Cornell Campus Map

Click on the campus map on the left to enlarge and view the location of the Payson Pavilion.

Cornell Researchers Discuss Device to Collect Living Prostate Tumor Cells: Video

On June 12, 2012, Cornell researchers David Nanus, Brian Kirby and Paraskevi Giannakakou discussed their new microfluidic device that collects circulating, living prostate cancer tumor cells from blood.

The research, conducted collaboratively between Cornell University and Weill Cornell Medical College, aims toward tailoring cancer treatment and improving patient survival. Click below to view the presentation.

Weill Cornell Investigators Among Grant Recipients to Study Metastatic Prostate Cancer

An international team of investigators from centers in the United States and the United Kingdom, including Weill Cornell Medical College, have been awarded a grant for $10 million over a three-year period to study the molecular underpinnings of metastatic prostate cancer while creating a comprehensive testing system to optimize personalized treatments.

Stand Up To Cancer (SU2C) and the Prostate Cancer Foundation (PCF), along with the American Association for Cancer Researc, SU2C’s scientific partner, announced the formation of a new “Dream Team” dedicated to prostate cancer research.

Weill Cornell Medical College investigators include Dr. Mark Rubin, the project’s principal investigator at Weill Cornell, and Dr. Himisha Beltran.

One of the project’s goals is to try to understand why therapies can become ineffective, despite working initially, and if patients may be treated with other types of therapies or participate in clinical trials. The researchers plan to develop cell line models to study tumor mutations to determine, for example, if they are the culprit behind such cancer recurrences in patients. In addition, the investigators plan to study novel combinations of drugs in clinical trials, including exploring the use of PARP inhibitors and drugs that inhibit the PTEN pathway, which is involved in cell signaling and growth. PTEN is a well known tumor suppressor gene. PARP inhibitors prevent an enzyme involved in DNA repair, especially in the repair of tumor cells, from working.

Click here to read more about the grant.